Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences Group (SLS) EBITDA Margin: 2020-2022

  • SELLAS Life Sciences Group's EBITDA Margin fell 163411.00% to -1,673.50% in Q1 2022 from the same period last year, while for Mar 2022 it was -378.90%, marking a year-over-year change of. This contributed to the annual value of -4,195.00% for FY2022, which is 386218.00% down from last year.
  • Latest data reveals that SELLAS Life Sciences Group reported EBITDA Margin of -1,673.50% as of Q1 2022, which was down 614.05% from -234.37% recorded in Q2 2021.
  • SELLAS Life Sciences Group's 5-year EBITDA Margin high stood at -39.39% for Q1 2021, and its period low was -1,673.50% during Q1 2022.
  • For the 3-year period, SELLAS Life Sciences Group's EBITDA Margin averaged around -541.54%, with its median value being -226.63% (2021).
  • Data for SELLAS Life Sciences Group's EBITDA Margin shows a maximum YoY plummeted of 163,411bps (in 2022) over the last 5 years.
  • SELLAS Life Sciences Group's EBITDA Margin (Quarterly) stood at -218.89% in 2020, then reached -234.37% in 2021, then slumped by 163,411bps to -1,673.50% in 2022.
  • Its EBITDA Margin was -1,673.50% in Q1 2022, compared to -234.37% in Q2 2021 and -39.39% in Q1 2021.